A good start of immunotherapy in esophageal cancer

Cancer Med. 2019 Aug;8(10):4519-4526. doi: 10.1002/cam4.2336. Epub 2019 Jun 23.


Considering the benefits of immunotherapy in advanced melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prognosis. There are a large number of clinical trials to study the application of immunotherapy such as immune checkpoint inhibitors, peptide vaccine, adoptive T cell transfer and oncolytic virus in esophageal cancer. Some already have preliminary results and show the advantages of immunotherapy in esophageal cancer, while others are still in progress. This review aims to introduce the feasibility and current status of immunotherapy in esophageal cancer.

Keywords: adoptive T-cell transfer; biomarker immune checkpoint inhibitor; esophageal cancer; immunotherapy; oncolytic virus; peptide vaccine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials as Topic
  • Esophageal Neoplasms / immunology
  • Esophageal Neoplasms / therapy*
  • Humans
  • Immunologic Factors / therapeutic use
  • Immunotherapy / methods*
  • Immunotherapy, Adoptive
  • Oncolytic Virotherapy
  • Treatment Outcome
  • Vaccines, Subunit / therapeutic use


  • Immunologic Factors
  • Vaccines, Subunit